Highlights Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-05-15 am EDT			5-day change	1st Jan Change
73.96 ^EUR	+0.98%		+1.18%	-10.59%

May. 14	Finance: Why the rich get the best deals
May. 14	Finance: Why we only lend to the wealthy

Highlights

May. 08	Berenberg Calls for More Acquisitions from Sanofi; Estimates Updated	MT
May. 06	Sanofi asks to pull diabetes drug out of FDA voucher program, STAT News reports	RE
May. 06	Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with review - Stat News	RE
May. 04	For final dividend	FA
May. 04	Sanofi Expands Artificial Intelligence Center of Excellence in Toronto	CI
Apr. 29	Regeneron beats quarterly estimates on Dupixent demand; shares fall on Eylea weakness	RE
Apr. 29	Sanofi Approves Ordinary Annual Dividend, Payable on May 7, 2026	CI
Apr. 29	Regeneron beats quarterly results estimates on strong Dupixent demand	RE
Apr. 27	Sanofi in the red as UBS maintains Neutral stance
Apr. 24	Sanofi sees profit-taking despite DZ Bank support
Apr. 24	Sanofi's Multiple Sclerosis Therapy Cenrifki Wins European Medicine Agency's Positive Opinion	MT
Apr. 24	Sanofi Recommends Cenrifki for EU Approval to Treat Secondary Progressive Multiple Sclerosis Without Relapses	CI
Apr. 23	Oddo BHF hails Sanofi's quarterly results and maintains bullish outlook
Apr. 23	Sanofi Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 23	Sanofi Affirms Earning Guidance for 2026	CI
Apr. 23	Sanofi Q1 Earnings, Net Sales Rise	MT
Apr. 23	Sanofi Q1 business operating income beats Vara consensus	RE
Apr. 23	Sanofi's first quarter earnings edges past estimates ahead of CEO change	RE
Apr. 23	Sanofi's solid earnings set stage for new CEO after drug trial 'setbacks'	RE
Apr. 23	Sanofi Posts Higher Sales Amid Leadership Transition	DJ
Apr. 23	Sanofi Posts Lower Q1 Net Income; Net Sales Rise	MT
Apr. 22	Sanofi, Regeneron's Dupixent Wins US FDA Nod for Young Children With CSU	MT
Apr. 22	Sanofi's Tzield Secures US FDA Nod for Expanded Indication in Children	MT
Apr. 22	US FDA Extends Review Period for Sanofi's Multiple Myeloma Therapy	MT
Apr. 22	Sanofi's Tzield approved in US to delay onset of stage 3 type 1 diabetes in young children	RE